LGALS3 and non-small cell lung carcinoma: Support for this comes from galectin-3 inhibition with the GB1211 structural analogue GB1107 which leads to a reduction in M2-like TAMs and increased infiltration and activity of CD8 + cytotoxic T lymphocytes within NSCLC tumors [7].